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Accumulating data have recently underlined argon´s neuroprotective potential. However, to
the best of our knowledge, no data are available on the cerebrovascular effects of argon (Ar)
in humans. We hypothesized that argon inhalation does not affect mean blood flow velocity
of the middle cerebral artery (Vmca), cerebral flow index (FI), zero flow pressure (ZFP),
effective cerebral perfusion pressure (CPPe), resistance area product (RAP) and the
arterio-jugular venous content differences of oxygen (AJVDO2), glucose (AJVDG), and lac-
tate (AJVDL) in anesthetized patients.
Materials and methods
In a secondary analysis of an earlier controlled cross-over trial we compared parameters of
the cerebral circulation under 15 minutes exposure to 70%Ar/30%O2 versus 70%N2/30%O2 in
29 male patients under fentanyl-midazolam anaesthesia before coronary surgery. Vmca was
measured by transcranial Doppler sonography. ZFP and RAP were estimated by linear
regression analysis of pressure-flow velocity relationships of the middle cerebral artery. CPPe
was calculated as the difference between mean arterial pressure and ZFP. AJVDO2, AJVDG
and AJVDL were calculated as the differences in contents between arterial and jugular-venous
blood of oxygen, glucose, and lactate. Statistical analysis was done by t-tests and ANOVA.
Results
Mechanical ventilation with 70% Ar did not cause any significant changes in mean arterial
pressure, Vmca, FI, ZFP, CPPe, RAP, AJVDO2, AJVDG, and AJVDL.
Discussion
Short-term inhalation of 70% Ar does not affect global cerebral circulation or metabolism in
male humans under general anaesthesia.
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Introduction
Argon is the longest known rare gas of the group of noble gases. Compared to xenon, it has a
higher natural abundance in the atmosphere (gas fraction of dry air at sea level: 20.9% oxygen,
78.1% nitrogen, 0.9% argon, 0.03% carbon dioxide, helium 0.000005%, and 0.00000009%
xenon) [1]. It can be obtained as a pure gas of pharmaceutical quality at low costs. Stable argon
gas is known to be inert. It does not change vital parameters and has no anaesthetic properties
at sea level [2,3]. When argon is administered by inhalation it does not require complex venti-
lator settings. Inhalation of argon/oxygen mixtures is used in humans to measure coronary [4]
and cerebral blood flow [5,6]. Argons beneficial neuroprotective and organoprotective proper-
ties have been observed in animal experiments in vitro and in vivo, but rarely in human studies
[7,8].
Up to now the cerebrovascular and cerebrometabolic effects of argon have not been investi-
gated in humans, which may be essential for a possible future clinical application of argon as
an organoprotective agent. We performed a larger series of clinical studies using an argon
inhalation method for measurements of global cerebral blood flow (CBF), a modification of
the Kety-Schmidt technique. In a prospective, controlled, cross-over study design, we investi-
gated the effects of hyperventilation versus hypoventilation in anesthetized patients on param-
eters of circulation and cerebral metabolism, which in part has been recently published [9]. In
the same group of patients we also investigated the short-term effects of argon inhalation. We
hypothesized that argon has no effects on parameters of cerebral blood flow velocity, cerebro-
vascular perfusion pressure, blood gas analysis, and global cerebral metabolism.
The original rationale for this substudy was a methodological question, as we wanted to
rule out the possibility, that our method of CBF measurement (which required argon inhala-
tion) per se might have any influence on the cerebrovascular and cerebrometabolic variables.
Because of the recent interest in potential organoprotective properties of argon, we believe that
these data should be made accessible to the scientific community.
Materials and methods
Design
In this prospective controlled study we investigated the cerebrovascular CO2-reactivity of
CBF, cerebral blood flow velocity of the middle cerebral artery (Vmca), and cerebral metabolic
rate of oxygen, glucose and lactate (CMRO2, CMRG, CMRL) in 30 patients before cardiovas-
cular surgery at the University of Go¨ttingen Medical Centre, Germany. CBF was measured
using the modified Kety-Schmidt inert gas saturation technique with stable argon gas as an
indicator (70% Ar / 30% O2 gas mixture). Vmca was simultaneously measured by transcranial
Doppler sonography (TCD) [9]. Subsequently, after this investigation of hypoventilation ver-
sus hyperventilation on CBF, Vmca and CMR, we divided the 30 patients into 3 subgroups (10
patients per group) for further examinations in the same setting. With additional measure-
ments in these patients we studied the cerebrovascular effects (i) of nitroglycerine [10], (ii) of
halothane [11], and (iii) of more extensive variations of PaCO2 [12].
For quality control purposes, we also studied in these patients the cerebrovascular and met-
abolic effects of argon itself at the beginning of each series of CBF measurements. The primary
rationale for this analysis was to investigate if our method of CBF measurement (argon satura-
tion method) per se has any influence on cerebrovascular circulation or metabolism. Thus hae-
modynamic and laboratory data, which have been used to calculate variables of the first point
of measurement in previous publications, are partly used in this analysis [9–12].
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Cerebral flow index (FI), effective cerebral perfusion pressure (CPPe), cerebral zero flow
pressure (ZFP), and the inverse slope of pressure-flow velocity relationships (resistance area
product, RAP) were calculated in addition to standard variables from transcranial Doppler
and haemodynamic recordings.
The study project followed the recommendations of the Declarations of Helsinki and the
European Union Commission and European Medicines Agency (Council Directive 91/507/
EEC and 75/318/EEC). Ethical approval for this study was provided by the Medical Ethical
Committee of the Georg-August-University of Go¨ttingen, Go¨ttingen, Niedersachsen, Ger-
many (Trial: Validation of transcranial Dopplersonography as a monitoring technique of the
cerebral circulation during general anaesthesia (Validierung der transkraniellen Dopplersono-
graphie als U¨berwachungsverfahren der zerebralen Ha¨modynamik unter ana¨sthesiologischen
Bedingungen), Ethical Committee N˚ 07/09/90). The trial has been retrospectively registered
at the German Clinical Trials Registry (No.: DRKS00011535).
Endpoints
The endpoints of the study were changes in the mean Vmca, FI, CPPe, ZFP, RAP, and the
arterio-jugularvenous content differences of oxygen (AJVDO2), glucose (AJVDG), and lactate,
(AJVDL). We hypothesized that in patients under intravenous anaesthesia short-term inhala-
tion of 70% argon does not alter cerebral haemodynamics or metabolism.
Inclusion
Due to logistical reasons and funding we could perform only 1–2 measurements per month.
Thus, standard-screening procedures could not be applied in this cross-over trial. Patients
were eligible for inclusion if scheduled for elective coronary surgery. Exclusion criteria were:
age older than 80 years, active neurological disease, and a history of cerebrovascular disease,
brain injury, or intracranial surgery.
Transcranial Doppler measurements of Vmca from the transtemporal window fail with
above average incidence in elderly female patients due to less mineral bone density and subse-
quently reduced ultrasound penetration [13]. Therefore, we included only male patients in
this study. All patients were informed about the purpose of the study and provided written
informed consent before being enrolled. None of the eligible patients refused inclusion in the
trial.
Anaesthesia procedure
Individual medications were continued until surgery. Intravenous anaesthesia was induced
and maintained by continuous intravenous administration of fentanyl, midazolam and pan-
curonium. All patients received two peripheral intravenous lines, an endotracheal tube, a
nasogastric tube, and a urine catheter. After arterial, central venous and pulmonary artery
catheterization a jugular bulb catheter was inserted by retrograde puncture of the right internal
jugular vein. The correct position of the jugular bulb catheter tip was verified by fluoroscopy
to prevent inadvertent extracerebral contamination of blood samples. The withdrawal rate of
blood samples used for blood gas analysis, metabolic tests and for gas chromatographic deter-
mination of the argon concentration at the end of the saturation period was 5 mL / 20 s [14].
The anaesthesia procedure, the details of mechanical ventilation and the methods of catheter
insertion have been described in previous reports in detail [5,9].
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Measurements and calculations
Measurements were performed in 30 patients after induction of general anaesthesia and before
surgery during haemodynamic and respiratory steady-state conditions.
First measurements were performed under 70%N2/30%O2, then ventilation was switched
to 70% argon/30%O2 mixture for 15 minutes. The ventilator settings have been adjusted fol-
lowing to our study protocol. All patients have been ventilated by two identical anaesthesia
machines. When starting the argon-wash-in-period we changed the ventilators, which had
been prefilled with the respective gas mixture, using identical respiratory settings and identical
inspired oxygen fraction. End-expiratory CO2 concentrations were continuously recorded to
ensure a stable PaCO2 during argon ventilation.
Blood samples were drawn twice, at the beginning (baseline) and end of the argon wash-in
period (argon), to measure variables of blood gas analysis (ABL; Radiometer, Copenhagen,
Denmark), glucose and lactate.
Blood flow velocity in the proximal (M1) segment of the middle cerebral artery (Vmca) was
measured by TCD. To ensure a constant position of the ultrasound probe during the investiga-
tion period, we used a probe holder (IMP2 monitoring probe holder, EME, U¨berlingen, Ger-
many). During measurements the patients’ heads were fixed in midline position. Arterial
blood pressure was measured invasively in the radial artery, ipsilateral to the TCD probe.
The analyses of the ZFP, CPPe and RAP have been performed after the study period. Cere-
bral ZFP was calculated from data at baseline and at the end of each argon gas saturation phase
from two simultaneous 10 s recordings (two breathing cycles) of the Vmca curves and arterial
pressure curves. Over each 10 s period we first averaged consecutive pairs of diastolic, mean
and systolic data of ABP and Vmca. These data were used to generate a pressure/flow velocity
plot. ZFP was then extrapolated by linear regression analysis of the ABP-Vmca relationship.
The ABP axis intercept of the regression line determines the ZFP [15,16]. The cerebral ZFP
was used as a measure of the effective downstream pressure of the cerebral circulation. Conse-
quently, CPPe was calculated as CPPe = mean ABP-ZFP. In the relationship between ABP and
Vmca, the RAP is defined as the inverse slope of their linear regression line [17,18].
Inside the spectral envelope each velocity has an intensity (usually color-coded on the dis-
play), which is proportional to the volume of blood at this velocity. The flow related to that vol-
ume of blood is therefore proportional to the product of its velocity and acoustic intensity.
Summing these different flows gives a flow index (FI), which is proportional to total flow. The
FI was thus computed as the sum of each acoustic intensity within the TCD spectrum multi-
plied by the corresponding velocity. We averaged all signals over the entire waveform, which
yields the mean FI for that particular 10 s interval [19–21].
The arterial-to-jugular venous concentration difference of a substance x, was calculated as
AJVD(x) = Ca(x)—Cjv(x). We calculated the difference in arterio-jugular venous content of
oxygen (AJVDO2), glucose (AJVDG), and lactate (AJVDL) [22]. By definition, positive AJVD
values indicate consumption or net influx, and negative values indicate production or net
efflux. For AJVDL, in case of cerebral lactate production, we thus expected negative values.
Statistical analysis
In this secondary analysis study setting a prior sample size calculation was not performed.
Each patient served as his own control. The results presented are expressed as mean (standard
deviation) unless otherwise stated. Normal distribution of data was assessed both visually with
inspection of histograms and with the D’Agostino-Pearson omnibus K2 method. The differ-
ences between baseline and argon gas inhalation were calculated using t-tests for paired data
or Welch-test and non-parametric Wilcoxon signed-rank test, if indicated [23]. To provide an
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estimate of the effect of argon gas and its clinical meaningfulness, we calculated mean differ-
ences (MD) and their 95 per cent confidence intervals (MD; 95% CI upper bound, lower
bound; P-value) [24]. In case of significant differences between the baseline and the argon
period, all primary endpoints were additionally tested by one-way ANOVA for repeated mea-
surements followed by Bonferoni multiple comparison tests in order to prevent type I error
[25].
All statistical analyses were performed two-sided and a p-value of p< 0.05 was considered
to be significant. Database sheets were done by MS Excel1 for Mac 2011 (Microsoft, Red-
mond, Washington, USA). Statistical procedures and graphs were made using Prism 6.0
(GraphPad Software, La Jolla, California, USA).
Results
The study period was 27 months (February 20, 1991 until May 10, 1993). A total of 30 male
patients were examined. In one patient an unexpected sudden increase in heart rate and blood
pressure occurred after an unintended surgical stretcher movement during the recordings.
This was interpreted as a short phase of insufficient depth of anaesthesia, which ceased follow-
ing an additional bolus of fentanyl and midazolam. The patient was thereafter completely
excluded from further analysis because we assumed insufficient steady state conditions.
The mean TCD-insonation depth of the MCA was 51 (3) mm. TCD signals were of high
quality in all patients except for two patients during the baseline measurement (patient 1 and
5). These data have been excluded from respective analysis.
Mean age of the included 29 patients was 56 (6) yrs. (median 57, range 41–65 yrs.), mean
height 174 (6) cm, and mean body weight 78 (8) kg. One of our patients had diabetes mellitus
type 2, treated with biguanides. None of the patients showed increased levels of blood glucose.
A minimal, but significant decrease of mean blood temperature between the two periods of
measurements was observed (Temp baseline 35.6 (0.5)˚C, argon 35.5 (0.5)˚C, MD 0.1, 95% CI
0.07 to 0.2, P< 0.01). There was a minimal decrease in heart rate (HR) baseline 58 (8) bpm
and argon 56 (8) bpm, MD 2; 95% CI 1 to 2, P< 0.01), arterial oxygen saturation (SaO2 base-
line 97 (1)% and argon 96 (2)%, MD 1, 95% CI 1 to 1, P< 0.01), and arterial partial pressure of
oxygen (PaO2 baseline 139 (42) mmHg and argon 109 (26) mmHg, MD 29, 95% CI 17 to 41,
P< 0.01). Arterial lactate concentration showed a very small but significant increase (LacART
baseline 0.59 (0.16) mmolL-1 and argon 0.63 (0.17) mmolL-1, MD -0.04, 95% CI −0.08 to
-0.01, P 0.04). Levels of haemoglobin were unchanged before and after argon exposure (Hb
baseline 12.7 (1.4) mgdL-1 and argon 12.7 (1.4) mgdL-1, MD 0.01, 95% CI −0.06 to 0.08, P
0.84) as well as levels of jugular venous oxygen saturation (SjvO2 baseline 50 (10)% and argon
50 (11)%, MD 0.44, 95% CI −0.78 to 1.67, P 0.46).
When comparing inhalation of 70% N2 / 30% O2 with 70% Ar / 30% O2 there were no sig-
nificant and clinically relevant changes in mean arterial pressure (MAP), mean Vmca, FI, ZFP,
CPPe, RAP AJVDO2, AJVDG and AJVDL.
The most important haemodynamic and metabolic data are presented in Table 1 and Fig 1.
There were no relevant changes in other basic haemodynamic and blood gas variables between
the baseline and argon inhalation period (see S1 Table and S1 File in the supplemental data
content).
Ventilation parameters and PaCO2 levels of the patients were effectively kept constant
(mean PaCO2 baseline = 36 (5) mmHg, (median 34, range 28 to 45), mean PaCO2 argon = 37
(7) mmHg (median 34, range 26 to 50). The mean difference of PaCO2 between the baseline
and the argon measurements was minimal MD = −0.6 (2.4), CI −1.5 to 0.36 mmHg, P 0.22
(median differences 0.0, P 0.46).
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Discussion
We investigated the effects of an argon-oxygen gas mixture on cerebral circulation and metab-
olism in cardiovascular patients under fentanyl-midazolam anaesthesia. The most prominent
result of our study is that no significant and clinically relevant changes were found in Vmca,
FI, CPPe, ZFP, RAP, AJVDO2, AJVDG and AJVDL when comparing inhalation of 70% Ar /
30% O2 with 70% N2 / 30% O2
To the best of our knowledge, this study is the first report about cerebrovascular and cere-
brometabolic effect of argon in humans. Most of the data on biological effects of argon has
been accomplished by in vitro and in vivo animal studies, but rarely in humans. Medical
research in the 1930s among military divers was one of the earliest observations of the biologi-
cal effects of argon. Argon is well known to be inert at standard gas conditions. Mental
impairment at high pressures had been observed [26, 27]. One trial in humans examined the
long-term effects (up to 9 days) under hyperbaric argon atmosphere, which showed no nega-
tive influence on work performance [28]. These data suggested a shift in lipid metabolism and
an increased resistance to hypoxic hypoxia under argon atmosphere. Other studies observed
an increase of oxygen consumption under argon, which was interpreted as a catalytic activity
of argon on oxygen kinetics [29]. Recently, Alderliesen et al. explored the potential effect of
argon ventilation on important physiological parameters in newborn piglets. Argon exposure
up to 80% did not change heart rate, arterial blood pressure, rectal temperature, arterial oxygen
saturation, amplitude-integrated electro-encephalogram and regional cerebral oxygen satura-
tion measured by near infrared spectrometry [3]. Our data in humans support these former
observations that argon inhalation did not cause relevant changes in basic vital parameters.
Transcranial Doppler sonography measures flow velocity in the basal cerebral arteries.
Today, Vmca and its indices are routinely used to assess components of cerebral circulation.
Although Vmca is not a direct measure of CBF, changes in flow velocity generally correlate
well with changes in CBF, except for specific situations, which may affect MCA diameter such
Table 1. Haemodynamic and metabolic data.
Baseline Argon n = 29
Variable mean SD mean SD Dimension MD CI limits P
meanVMCA 36 11 36 11 [cms-1] 0 (-0.5; 0.4) 0.87*
FI #$ 154 84 147 74 [] 7 (-4; 17) 0.20*
MAP 74 12 73 13 [mmHg] 1 (-1; 3) 0.33§
ZFP #$ 20 8 20 8 [mmHg] 0 (-2; 2) 0.91*
CPPe 54 14 53 13 [mmHg] 1 (-2; 4) 0.60*
RAP #$ 1.65 0.56 1.59 0.48 [mmHgscm-1] 0.06 (-0.03; 0.15) 0.18*
AJVDO2 8.5 2.0 8.3 2.4 [ml dL-1] 0.2 (-0.1; 0.4) 0.12
AJVDG# 10.1 4.6 9.1 4.1 [mg dL-1] 1.1 (-0.5; 2.6) 0.18
AJVDL#$ -0.06 0.07 -0.04 0.11 [mmol L-1] 0.02 (-0.07; 0.02) 0.26
Baseline = inhalation of 70% N2 / 30% O2. Argon = inhalation with 70% Ar / 30% O2. The P values, which refer to the difference between two measurement
points, were calculated using two-sided t-test for paired data. Because the variances of some outcome variables differed between two measurement points,
these parameters were additionally examined by Welch test (#) and nonparametric Wilcoxon signed-rank test ($) (P<0.05). Due to artefacts during TCD or
blood pressure recording, data of patient 1 and 5 have been excluded from respective analysis § n = 28, * n = 27.
AJVDG = arterio-jugular venous difference in glucose; AJVDL = arterio-jugular venous difference in lactate; AJVDO2 = arterio-jugular venous difference in
oxygen, CI = confidence interval (5%; 95%), CPPe = effective cerebral perfusion pressure defined as MAP-ZFP, FI = Flow index, MAP = mean arterial
pressure, MD = mean differences, RAP = resistance area product, SD = standard deviation, mean Vmca = mean blood flow velocity of the middle cerebral
artery, ZFP = zero flow pressure.
doi:10.1371/journal.pone.0171962.t001
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Fig 1. Effect of argon inhalation on cerebral circulation and metabolism. Values of mean blood flow velocity
of the middle cerebral artery (Vmca), effective cerebral perfusion pressure (CPPe), resistance area product
(RAP), arterio-jugular venous differences in oxygen (AJVDO2) glucose (AJVDG), and lactate (AJVDL) during
baseline (70%N2/30%O2) compared with argon inhalation (70%Ar/30%O2). Straight lines link individual values for
each subject. Data are mean (SD) for each measurement. The P values, which refer to the difference between two
measurement points, were calculated using two-sided t-test for paired data. Due to artefacts during TCD
recording, data of patient 1 and 5 have been excluded from respective analysis § n = 28, * n = 27.
doi:10.1371/journal.pone.0171962.g001
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as vasospasm, hypercapnia, migraine attacks, nitroglycerine, or other vasoactive agents [30–
32]. In our study we additionally monitored the sonographic flow index, which showed consis-
tent results when compared with Vmca. We thus have no reason to assume that a possible
change in CBF during argon exposure has not been detected by our TCD measurements
because of methodological limitations.
The noble gas xenon has excellent narcotic properties and may affect cerebral circulation
[33, 34]. Trials about the effect of xenon on CBF showed inconsistent results in animals and
humans [35–39]. The dose of xenon inhalation, however, seems to play an important role. In
monkeys, subanaesthetic xenon (35%) caused a global reduction in CBF [37], whereas anaes-
thetic concentration (80%) increased CBF by 53% [40]. Using the 133-xenon clearance
method, subanaesthetic (35%) xenon was shown to increase human rCBF by approximately
12% [41]. A recent investigation under steady conditions showed that anaesthetic concentra-
tion of xenon (65%) decreased regional CBF in several brain regions in animals and in
humans. The greatest decreases were detected in the cerebellum (-35%), the thalamus (-23%)
and the parietal cortex (-11%) [42]. However, xenon anaesthesia increases flow velocity of
basal cerebral arteries by about 30% [43,44]. The inconsistency of these results may partly be
explained by methodological reasons such as inconstant carbon dioxide levels, different anaes-
thetic agents and by interspecies differences in anaesthetic concentrations for xenon in animals
and in humans [42]. Argon has, in contrast to xenon, no anaesthetic properties at sea level
[45]. Up to now there are no reports about the effects of argon on cerebral circulation obtained
by TCD. Our data demonstrate that inhalation of 70% argon in humans did not affect Vmca
or cerebral FI.
Cerebral ZFP, CPPe and RAP are supplemental determinants of cerebral blood flow. Using
the CPPe as the driving pressure of the cerebral circulation does not require invasive measure-
ments of intracranial pressure (ICP) and offers advantages in understanding pathophysiology,
because changes of the effective downstream pressure irrespective of ICP will also be reflected
by this kind of calculation [12,15]. The inverse of the slope of the arterial blood pressure-Vmca
plot, the RAP, has been used as index of cerebrovascular resistance [12]. These less invasive
methods of assessing cerebral perfusion are well established and have improving accuracy
[46]. In our study, inhalation of argon showed no clinically relevant changes in ZFP, CPPe,
and RAP.
Reports on the effect of argon on CBF and parameters of cerebral metabolism are not avail-
able up to now. Global cerebral hypoperfusion often is defined as a SjvO2 less than 50%
whereas cerebral ischemia is assumed when SjvO2 is less than 40% and AJVDO2 is greater
than 9 mldL-1 [47]. Total intravenous anaesthesia with fentanyl/midazolam in humans causes
a moderate proportional reduction in CBF due to a decrease in both cerebrovascular resistance
and CMRO2 [5, 48]. Thus, a constant SjvO2 and unchanged arterio-jugular venous content
differences of oxygen, glucose, and lactate (AJVDO2, AJVDG, AJVDL) suggest intact flow-
metabolic coupling of the brain [22, 49]. In contrast to intravenous anaesthesia, volatile anaes-
thetics cause a partial uncoupling of CBF and metabolism because of a direct cerebral vasodila-
tatory effect [50, 51]. In our patients inhalation of 70% argon showed no clinically relevant
changes in SjvO2 and/or arterio-jugular venous content difference of oxygen, glucose, and lac-
tate. The coupling of cerebral flow and metabolism thus seems to be unchanged during argon
exposure and our findings indicate a constant cerebral metabolic rate of oxygen and glucose.
Despite the increasing comprehension of neuroplasticity and neuroprotection, the exact
mechanisms by which argon improves outcome remain far from being understood [52].
Besides an interference with neuronal ion-gated channels and cellular signalling pathways as
well as anti-apoptotic effects, the modulation of neuroinflammation seems to play a crucial
role [53]. Neuroprotective effects of argon were observed at different concentrations (25%,
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50% and 74%) in both in vitro models of cerebral ischemia and traumatic brain injury [54].
Bru¨cken and colleagues demonstrated in rats that one hour of 70% argon inhalation after car-
diac arrest provided a significant reduction in histopathological damage of the neocortex and
hippocampus, and was associated with a marked improvement in functional neurological
recovery. At baseline, as well as after 4 hours after cardiac arrest, no significant differences
were observed with regard to haemodynamics, variables of gas exchange, or lactate and glucose
concentrations between groups [55]. In a postresuscitation treatment study in pigs, 70% argon
inhalation lead to a fast and complete neurological recovery 72 hours after cardiopulmonary
resuscitation. In perinatal asphyxia animal models with piglets, ventilation with up to 80%
argon during normoxia, and 50% argon after hypoxia did not affect heart rate, blood pressure,
cerebral saturation and electrocortical brain activity [3].
Our study was not designed to assess the neuroprotective effect of argon ventilation. Based
on our observations and the previous, safe use of argon in adults in the past, as well as the
efficacy studies described above, further safety studies in humans (e.g. after cardiac arrest,
cerebral ischemia, traumatic brain injury, or even in neonates with perinatal asphyxia) appear
warranted.
Some methodological aspects of our study have to be considered.
The type of anaesthesia may have potential influence on the results of our study. We have
no reason to assume that intravenous anaesthesia with fentanyl and midazolam per se may
have confounded our results. However, the results of this study cannot a priori be extrapolated
to other types of anaesthesia. Similarly, the external validity of our data could be limited by the
fact that some of our patients with coronary artery disease might be suffering from concomi-
tant asymptomatic cerebrovascular disease.
Unexpectedly, there was a very slight reduction in SaO2 and PaO2. All patients have been
ventilated by two identical anaesthesia machines. When starting the argon-wash-in-period we
changed the ventilators, using identical respiratory settings and identical inspired oxygen frac-
tion. The mild decrease in SaO2 and PaO2 might be related to the short discontinuation of
PEEP during this manoeuvre. Fortunately, our measurements did not affect general conditions
in our patients. All surgical procedures were without complications. All patients had been dis-
charged from ICU within 2 days. There were no suspected unexpected serious adverse reac-
tions (SUSARS) or serious adverse events (SAE).
Conclusion
In male cardiac surgical patients under fentanyl-midazolam anaesthesia, short-term ventila-
tion with argon (70%Ar / 30% O2) did not show any effects on the cerebral circulation or on
global oxygen and glucose metabolism. The lack of cerebrovascular and cerebrometabolic
effects suggests future studies on the use of argon which should confirm the safety of argon
inhalation during longer periods and may investigate the organ protective effects of argon in
humans.
Supporting information
S1 File. Study data file. No legend.
(XLSX)
S1 Table. Effect of argon on parameters of blood gas analysis and haemodynamics.
Baseline = inhalation of 70% N2 / 30% O2. Argon = inhalation with 70% Ar / 30% O2. The P
values, which refer to the difference between two measurement points, were calculated using
two-sided t-test for paired data ( P<0.05). Due to artefacts during blood pressure recording,
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data of patient 1 has been excluded from respective analysis § n = 28. CI = confidence interval
(5%; 95%), GlucART = arterial blood glucose concentration, GlucJV = jugular bulb blood glu-
cose concentration, Hb = haemoglobin concentration, Hct = haematocrit, HR = heart rate
in beats per minute, K = serum potassium concentration, LacART = arterial blood lactate
concentration, LacJV = jugular bulb blood lactate concentration, MD = mean differences,
MAP = mean arterial blood pressure, Na = serum sodium concentration, pHART = pH of arte-
rial blood, pHJV = pH of jugular bulb blood, PaCO2 = arterial partial pressure of CO2, PjvCO2
= jugular bulb partial pressure of CO2, PaO2 = arterial partial pressure of O2, PjvO2 = jugular
bulb partial pressure of O2, SaO2 = arterial blood oxygen saturation, SjvO2 = jugular bulb
blood oxygen saturation, SBC = standard bicarbonate concentration, SD = standard deviation.
(DOCX)
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